US2006148869A1PendingUtilityA1
Halogenated biaryl heterocyclic compounds and methods of making and using the same
Est. expiryDec 17, 2023(expired)· nominal 20-yr term from priority
Inventors:Shili ChenJiacheng ZhouYusheng WuDeping WangJoseph M. SalvinoAdegboyega K. OyelereRongliang LouAshoke BhattacharjeeYi Chen
A61P 43/00A61P 31/12A61P 33/00A61P 35/00A61P 31/10A61P 31/00A61P 29/00A61P 21/00C07D 263/20
45
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates generally to the field of anti-infective anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having at least one halogenated hydrocarbon moiety, a biaryl moiety, and at least one heterocyclic moiety, that are useful as such agents.
Claims
exact text as granted — not AI-modified1 .- 45 . (canceled)
46 . A method of treating a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds having the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:
A is phenyl;
B is selected from the group consisting of:
phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;
Het-CH 2 —R 3 is selected from the group consisting of:
M is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein
i) any of a)-c) is substituted with one or more moieties selected from the group consisting of F, Cl, Br, and I; and
ii) any of a)-c) optionally is further substituted with one or more R 4 groups;
X is selected from the group consisting of:
a) —O—, b) —NR 5 —, c) —N(O), d) —N(OR 5 )—, e) —S(O) p —, f) —NR 5 —N═, g) ═N—NR 5 —, h) —O—N═, i) ═N—O—, j) —N═, k) ═N—, l) —NR 5 —NR 5 —, m) —NR 5 C(O)O—, n) —OC(O)NR 5 —, o) —NR 5 C(O)NR 5 —, p) —NR 5 C(NR 5 )NR 5 —, and
L is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein any of a)-c) optionally is substituted with one or more R 4 groups;
R 1 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 2 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 3 is selected from the group consisting of:
a) —OR 7 , b) —NR 7 R 7 , c) —C(O)R 7 , d) —C(O)OR 7 , e) —OC(O)R 7 , f) —C(O)NR 7 R 7 , g) —NR 7 C(O)R 7 , h) —OC(O)NR 7 R 7 , i) —NR 7 C(O)OR 7 , j) —NR 7 C(O)NR 7 R 7 , k) —C(S)R 7 , l) —C(S)OR 7 , m) —OC(S)R 7 , n) —C(S)NR 7 R 7 , o) —NR 7 C(S)R 7 , p) —OC(S)NR 7 R 7 , q) —NR 7 C(S)OR 7 , r) —NR 7 C(S)NR 7 R 7 , s) —NR 7 C(NR 7 )NR 7 R 7 , t) —S(O) p R 7 , u) —SO 2 NR 7 R 7 , and v) R 7 ;
R 4 , at each occurrence, independently is selected from the group consisting of:
a) H, b) F, c) Cl, d) Br, e) I, f) ═O, g) ═S, h) ═NR 5 , i) ═NOR 5 , j) ═N—NR 5 R 5 , k) —CF 3 , l) —OR 5 , m) —CN, n) —NO 2 , o) —NR 5 R 5 , p) —C(O)R 5 , q) —C(O)OR 5 , r) —OC(O)R 5 , s) —C(O)NR 5 R 5 , t) —NR 5 C(O)R 5 , u) —OC(O)NR 5 R 5 , v) —NR 5 C(O)OR 5 w) —NR 5 C(O)NR 5 R 5 , x) —C(S)R 5 , y) —C(S)OR 5 , z) —OC(S)R 5 , aa) —C(S)NR 5 R 5 , bb) —NR 5 C(S)R 5 , cc) —OC(S)NR 5 R 5 , dd) —NR 5 C(S)OR 5 , ee) —NR 5 C(S)NR 5 R 5 , ff) —NR 5 C(NR)NR 5 R 5 , gg) —S(O) p R 5 , and hh) R 5 ;
R 5 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) —C(O)—C 1-6 alkyl, f) —C(O)—C 2-6 alkenyl, g) —C(O)—C 2-6 alkynyl, h) —C(O)O—C 1-6 alkyl, i) —C(O)O—C 2-6 alkenyl, and j) —C(O)O—C 2-6 alkynyl,
wherein any of b)-j) optionally is substituted with one or more R 6 groups;
R 6 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, and u) —S(O) p C 1-6 alkyl;
R 7 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)C 1-6 alkyl, h) —C(O)—C 2-6 alkenyl, i) —C(O)—C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more R 8 groups;
R 8 , at each occurrence, is independently selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) ═O, f) ═S, g) ═NR 9 , h) ═NOR 9 , i) ═N—NR 9 R 9 , j) —CF 3 , k) —OR 9 , l) —CN, m) —NO 2 , n) —NR 9 R 9 , o) —C(O)R 9 , p) —C(O)OR 9 , q) —OC(O)R 9 , r) —C(O)NR 9 R 9 , s) —NR 9 C(O)R 9 , t) —OC(O)NR 9 R 9 , u) —NR 9 C(O)OR 9 , v) —NR 9 C(O)NR 9 R 9 , w) —C(S)R 9 , x) —C(S)OR 9 , y) —OC(S)R 9 , z) —C(S)NR 9 R 9 , aa) —NR 9 C(S)R 9 , bb) —OC(S)NR 9 R 9 , cc) —NR 9 C(S)OR 9 , dd) —NR 9 C(S)NR 9 R 9 , ee) —NR 9 C(NR 9 )NR 9 R 9 , ff) —S(O) p R 9 , gg) —SO 2 NR 9 R 9 , and hh) R 9 ;
R 9 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)—C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more moieties selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, u) —SO 2 NH 2 —, v) —SO 2 NHC 1-6 alkyl, w) —SO 2 N(C 1-6 alkyl) 2 , and x) —S(O) p C 1-6 alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, or 4; and
p, at each occurrence, independently is 0, 1, or 2.
47 .- 52 . (canceled)
53 . A method of treating a disorder in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds having the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:
A is phenyl;
B is selected from the group consisting of:
phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;
Het-CH 2 —R 3 is selected from the group consisting of:
M is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein
i) any of a)-c) is substituted with one or more moieties selected from the group consisting of F, Cl, Br, and I; and
ii) any of a)-c) optionally is further substituted with one or more R 4 groups;
X is selected from the group consisting of:
a) —O, b) —NR 5 —, c) —N(O), d) —N(OR 5 )—, e) —S(O) p —, f) —NR 5 —N═, g) ═N—NR 5 —, h) —O—N═, i) ═N—O—, j) —N═, k) ═N—, l) —NR 5 —NR 5 —, m) —NR 5 C(O)O—, n) —OC(O)NR 5 —, o) —NR 5 C(O)NR 5 —, p) —NR 5 C(NR 5 )NR 5 —, and
L is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein any of a)-c) optionally is substituted with one or more R 4 groups;
R 1 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 2 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 3 is selected from the group consisting of:
a) —OR 7 , b) —NR 7 R 7 , c) —C(O)R 7 , d) —C(O)OR 7 , e) —OC(O)R 7 , f) —C(O)NR 7 R 7 , g) —NR 7 C(O)R 7 , h) —OC(O)NR 7 R 7 , i) —NR 7 C(O)OR 7 , j) —NR 7 C(O)NR 7 R 7 , k) —C(S)R 7 , l) —C(S)OR 7 , m) —OC(S)R 7 , n) —C(S)NR 7 R 7 , o) —NR 7 C(S)R 7 , p) —OC(S)NR 7 R 7 , q) —NR 7 C(S)R 7 , r) —NR 7 C(S)NR 7 R 7 , s) —NR 7 C(NR 7 )NR 7 R 7 , t) —S(O) p R 7 , u) —SO 2 NR 7 R 7 , and v) R 7 .
R 4 , at each occurrence, independently is selected from the group consisting of:
a) H, b) F, c) Cl, d) Br, e) I, f) ═O, g) ═S, h) ═NR 5 , i) ═NOR 5 , j) ═N—NR 5 R 5 , k) —CF 3 , l) —OR 5 , m) —CN, n) —NO 2 , o) —NR 5 R 5 , p) —C(O)R 5 , q) —C(O)OR 5 , r) —OC(O)R 5 , s) —C(O)NR 5 R 5 , t) —NR 5 C(O)R 5 , u) —OC(O)NR 5 R 5 , v) —NR 5 C(O)OR 5 , w) —NR 5 C(O)NR 5 R 5 , x) —C(S)R 5 , y) —C(S)OR 5 , z) —OC(S)R 5 , aa) —C(S)NR 5 R 5 , bb) —NR 5 C(S)R 5 , cc) —OC(S)NR 5 R 5 , dd) —NR C(S)OR 5 , ee) —NR C(S)NR 5 R 5 , ff) —NR 5 C(NR 5 )NR 5 R 5 , gg) —S(O) p R 5 , and hh) R 5 ;
R 5 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) —C(O)C 1-6 alkyl, f) —C(O)—C 2-6 alkenyl, g) —C(O)—C 2-6 alkynyl, h) —C(O)O—C 1-6 alkyl, i) —C(O)O—C 2-6 alkenyl, and j) —C(O)O—C 2-6 alkynyl,
wherein any of b)-j) optionally is substituted with one or more R 6 groups;
R 6 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, and u) —S(O) p C 1-6 alkyl;
R 7 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more R 8 groups;
R 8 , at each occurrence, is independently selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) ═O, f) ═S, g) ═NR 9 , h) ═NOR 9 , i) ═N—NR 9 R 9 , j) —CF 3 , k) —OR 9 , l) —CN, m) —NO 2 , n) —NR 9 R 9 , o) —C(O)R 9 , p) —C(O)OR 9 , q) —OC(O)R 9 , r) —C(O)NR 9 R 9 , s) —NR 9 C(O)R 9 , t) —OC(O)NR 9 R 9 , u) —NR 9 C(O)OR 9 , v) —NR 9 C(O)NR 9 R 9 , w) —C(S)R 9 , x) —C(S)OR 9 , y) —OC(S)R 9 , z) —C(S)NR 9 R 9 , aa) —NR 9 C(S)R 9 , bb) —OC(S)NR 9 R 9 , cc) —NR 9 C(S)OR 9 , dd) —NR 9 C(S)NR 9 R 9 , ee) —NR 9 C(NR 9 )NR 9 R 9 , ff) —S(O) p R 9 , gg) —SO 2 NR 9 R 9 , and hh) R 9 ;
R 9 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)—C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more moieties selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, u) —SO 2 NH 2 —, v) —SO 2 NHC 1-6 alkyl, w) —SO 2 N(C 1-6 alkyl) 2 , and x) —S(O) p C 1-6 alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, or 4; and
p, at each occurrence, independently is 0, 1, or 2;
thereby to ameliorate a symptom of the disorder, wherein the disorder is selected from the group consisting of: a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant Staphylococcus aureus infection, a vancomycin-resistant Enterococci infection, a linezolid-resistant organism infection, and tuberculosis.
54 . The method according to claim 46 , wherein the compound is administered orally, parentally, or topically.
55 .- 57 . (canceled)
58 . The method according to claim 53 , wherein the compound is administered orally, parentally, or topically.
59 . The method according to claim 46 , comprising administering one or more compounds having the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, L, M, R 1 , R 3 , X, and m are defined as described in claim 46 .
60 . The method according to claim 53 , comprising administering one or more compounds having the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof,
wherein A, L, M, R 1 , X, and m are defined as described in claim 53 .
61 . The method according to claim 59 , wherein the compound is administered orally, parentally, or topically.
62 . The method according to claim 60 , wherein the compound is administered orally, parentally, or topically.
63 . A method of treating a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds having the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:
A is phenyl;
B is selected from the group consisting of:
phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;
Het-CH 2 —R 3 is selected from the group consisting of:
M is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein
i) any of a)-c) is substituted with one or more moieties selected from the group consisting of F, Cl, Br, and I; and
ii) any of a)-c) optionally is further substituted with one or more R 4 groups;
X is selected from the group consisting of:
a) —O—, b) —NR 5 —, c) —N(O), d) —N(OR 5 )—, e) —S(O) p —, f) —NR 5 —N═, g) ═N—NR 5 —, h) —O—N═, i) ═N—O—, j) —N═, k) ═N—, l) —NR 5 —NR 5 —, m) —NR 5 C(O)O—, n) —OC(O)NR 5 —, o) —NR 5 C(O)NR 5 —, p) —NR 5 C(NR 5 )NR 5 —, and
L is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein any of a)-c) optionally is substituted with one or more R 4 groups;
R 1 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 2 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 3 is selected from the group consisting of:
a) —NR 7 R 7 , b) —C(O)R 7 , c) —C(O)OR 7 , d) —OC(O)R 7 , e) —C(O)NR 7 R 7 , f) —NR 7 C(O)R 7 , g) —OC(O)NR 7 R 7 , h) —NR 7 C(O)OR 7 , i) —NR 7 C(O)NR 7 R 7 , j) —C(S)R 7 , k) —C(S)OR 7 , l) —OC(S)R 7 , m) —C(S)NR 7 R 7 , n) —NR 7 C(S)R 7 , o) —OC(S)NR 7 R 7 , p) —NR 7 C(S)OR 7 , q) —NR 7 C(S)NR 7 R 7 , r) —NR 7 C(NR 7 )NR 7 R 7 , s) —SOR 7 , t) —SO 2 R 7 , u) —SO 2 NR 7 R 7 , and v) R 7 ;
R 4 , at each occurrence, independently is selected from the group consisting of:
a) H, b) F, c) Cl, d) Br, e) I, f) ═O, g) ═S, h) ═NR 5 , i) ═NOR 5 , j) ═N—NR 5 R 5 , k) —CF 3 , l) —OR 5 , m) —CN, n) —NO 2 , o) —NR 5 R 5 , p) —C(O)R 5 , q) —C(O)OR 5 , r) —OC(O)R 5 , s) —C(O)NR 5 R 5 , t) —NR 5 C(O)R 5 , u) —OC(O)NR 5 R 5 , v) —NR 5 C(O)OR 5 , w) —NR 5 C(O)NR 5 R 5 , x) —C(S)R 5 , y) —C(S)OR 5 , z) —OC(S)R 5 , aa) —C(S)NR 5 R 5 , bb) —NR 5 C(S)R 5 , cc) —OC(S)NR 5 R 5 , dd) —NR 5 C(S)OR 5 , ee) —NR 5 C(S)NR 5 R 5 , ff) —NR 5 C(NR 5 )NR 5 R 5 , gg) —S(O) p R 5 , and hh) R 5 ;
R 5 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) —C(O)C 1-6 alkyl, f) —C(O)C 2-6 alkenyl, g) —C(O)—C 2-6 alkynyl, h) —C(O)O—C 1-6 alkyl, i) —C(O)O—C 2-6 alkenyl, and j) —C(O)O—C 2-6 alkynyl,
wherein any of b)-j) optionally is substituted with one or more R 6 groups;
R 6 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, and u) —S(O) p C 1-6 alkyl;
R 7 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more R 8 groups;
R 8 , at each occurrence, is independently selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) ═O, f) ═S, g) ═NR 9 , h) ═NOR 9 , i) ═N—NR 9 R 9 , j) —CF 3 , k) —OR 9 , l) —CN, m) —NO 2 , n) —NR 9 R 9 , o) —C(O)R 9 , p) —C(O)OR 9 , q) —OC(O)R 9 , r) —C(O)NR 9 R 9 , s) —NR 9 C(O)R 9 , t) —OC(O)NR 9 R 9 , u) —NR 9 C(O)OR 9 , v) —NR 9 C(O)NR 9 R 9 , w) —C(S)R 9 , x) —C(S)OR 9 , y) —OC(S)R 9 , z) —C(S)NR 9 R 9 , aa) —NR 9 C(S)R 9 , bb) —OC(S)NR 9 R 9 , cc) —NR 9 C(S)OR 9 , dd) —NR 9 C(S)NR 9 R 9 , ee) —NR 9 C(NR 9 )NR 9 R 9 , ff) —S(O) p R 9 , gg) —SO 2 NR 9 R 9 , and hh) R 9 ;
R 9 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)—C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more moieties selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, u) —SO 2 NH 2 —, v) —SO 2 NHC 1-6 alkyl, w) —SO 2 N(C 1-6 alkyl) 2 , and x) —S(O) p C 1-6 alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, or 4; and
p, at each occurrence, independently is 0, 1, or 2.
64 . A method of treating a disorder in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds having the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:
A is phenyl;
B is selected from the group consisting of:
phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;
Het-CH 2 —R 3 is selected from the group consisting of:
M is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein
i) any of a)-c) is substituted with one or more moieties selected from the group consisting of F, Cl, Br, and I; and
ii) any of a)-c) optionally is further substituted with one or more R 4 groups;
X is selected from the group consisting of:
a) —O—, b) —NR 5 —, c) —N(O), d) —N(OR 5 )—, e) —S(O) p —, f) —NR 5 —N═, g) ═N—NR 5 —, h) —O—N═, i) ═N—O—, j) —N═, k) ═N—, l) —NR 5 —NR 5 —, m) —NR 5 C(O)O—, n) —OC(O)NR 5 —, o) —NR 5 C(O)NR 5 —, p) —NR 5 C(NR 5 )NR 5 —, and
L is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein any of a)-c) optionally is substituted with one or more R 4 groups;
R 1 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 2 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 , R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 3 is selected from the group consisting of:
a) —NR 7 R 7 , b) —C(O)R 7 , c) —C(O)OR 7 , d) —OC(O)R 7 , e) —C(O)NR 7 R 7 , f) —NR 7 C(O)R 7 , g) —OC(O)NR 7 R 7 , h) —NR 7 C(O)OR 7 , i) —NR 7 C(O)NR 7 R 7 , j) —C(S)R 7 , k) —C(S)OR 7 , l) —OC(S)R 7 , m) —C(S)NR 7 R 7 , n) —NR 7 C(S)R 7 , o) —OC(S)NR 7 R 7 , p) —NR 7 C(S)OR 7 , q) —NR 7 C(S)NR 7 R 7 , r) —NR 7 C(NR 7 )NR 7 R 7 , s) —SOR 7 , t) —SO 2 R 7 , u) —SO 2 NR 7 R 7 , and v) R 7 ;
R 4 , at each occurrence, independently is selected from the group consisting of:
a) H, b) F, c) Cl, d) Br, e) I, f) ═O, g) ═S, h) ═NR 5 , i) ═NOR 5 , j) ═N—NR 5 R 5 , k) —CF 3 , l) —OR 5 , m) —CN, n) —NO 2 , o) —NR 5 R 5 , p) —C(O)R 5 , q) —C(O)OR 5 , r) —OC(O)R 5 , s) —C(O)NR 5 R 5 , t) —NR 5 C(O)R 5 , u) —OC(O)NR 5 R 5 , v) —NR 5 C(O)OR 5 , w) —NR 5 C(O)NR 5 R 5 , x) —C(S)R 5 , y) —C(S)OR 5 , z) —OC(S)R 5 , aa) —C(S)NR 5 R 5 , bb) —NR 5 C(S)R 5 , cc) —OC(S)NR 5 R 5 , dd) —NR 5 C(S)OR 5 , ee) —NR 5 C(S)NR 5 R 5 , ff) —NR 5 C(NR 5 )NR 5 R 5 , gg) —S(O) p R 5 , and hh) R 5 ;
R 5 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) —C(OC 1-6 alkyl, f) —C(O)C 2-6 alkenyl, g) —C(O)C 2-6 alkynyl, h) —C(O)O—C 1-6 alkyl, i) —C(O)O—C 2-6 alkenyl, and j) —C(O)O—C 2-6 alkynyl,
wherein any of b)-j) optionally is substituted with one or more R 6 groups;
R 6 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, and u) —S(O) p C 1-6 alkyl;
R 7 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more R 8 groups;
R 8 , at each occurrence, is independently selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) ═O, f) ═S, g) ═NR 9 , h) ═NOR 9 , i) ═N—NR 9 R 9 , j) —CF 3 , k) —OR 9 , l) —CN, m) —NO 2 , n) —NR 9 R 9 , o) —C(O)R 9 , p) —C(O)OR 9 , q) —OC(O)R 9 , r) —C(O)NR 9 R 9 , s) —NR 9 C(O)R 9 , t) —OC(O)NR 9 R 9 , u) —NR 9 C(O)OR 9 , v) —NR 9 C(O)NR 9 R 9 , w) —C(S)R 9 , x) —C(S)OR 9 , y) —OC(S)R 9 , z) —C(S)NR 9 R 9 , aa) —NR 9 C(S)R 9 , bb) —OC(S)NR 9 R 9 , cc) —NR 9 C(S)OR 9 , dd) —NR 9 C(S)NR 9 R 9 , ee) —NR 9 C(NR 9 )NR 9 R 9 , ff) —S(O) p R 9 , gg) —SO 2 NR 9 R 9 , and hh) R 9 ;
R 9 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)—C 1-6 alkyl, h) —C(O)—C 2-6 alkenyl, i) —C(O)—C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more moieties selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, u) —SO 2 NH 2 —, v) —SO 2 NHC 1-6 alkyl, w) —SO 2 N(C 1-6 alkyl) 2 , and x) —S(O) p C 1-6 alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, or 4; and
p, at each occurrence, independently is 0, 1, or 2;
thereby to ameliorate a symptom of the disorder, wherein the disorder is selected from the group consisting of: a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant Staphylococcus aureus infection, a vancomycin-resistant Enterococci infection, a linezolid-resistant organism infection, and tuberculosis.
65 . The method according to claim 63 , wherein the compound is administered orally, parentally, or topically.
66 . The method according to claim 64 , wherein the compound is administered orally, parentally, or topically.
67 . A method of treating a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds having the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:
A is phenyl;
B is selected from the group consisting of:
phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;
Het-CH 2 —R 3 is selected from the group consisting of:
M is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein
i) any of a)-c) is substituted with one or more moieties selected from the group consisting of F, Cl, Br, and I; and
ii) any of a)-c) optionally is further substituted with one or more R 4 groups;
X is selected from the group consisting of:
a) —O—, b) —NR 5 —, c) —N(O)—, d) —N(OR 5 )—, e) —S(O) p —, f) —NR 5 —N═, g) ═N—NR 5 —, h) —O—N═, i) ═N—O—, j) —N═, k) ═N—, l) —NR 5 —NR 5 —, m) —NR 5 C(O)O—, n) —OC(O)NR 5 —, o) —NR 5 C(O)NR 5 —, p) —NR 5 C(NR 5 )NR 5 —, and
L is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein any of a)-c) optionally is substituted with one or more R 4 groups;
R 1 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 2 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 3 is selected from the group consisting of:
a) —OR 7 , b) —NR 7 R 7 , c) —C(O)R 7 , d) —C(O)OR 7 , e) —OC(O)R 7 , f) —C(O)NR 7 R 7 , g) —NR 7 C(O)R 7 , h) —OC(O)NR 7 R 7 , i) —NR 7 C(O)OR 7 , j) —NR 7 C(O)NR 7 R 7 , k) —C(S)R 7 , l) —C(S)OR 7 , m) —OC(S)R 7 , n) —C(S)NR 7 R 7 , o) —NR 7 C(S)R 7 , p) —OC(S)NR 7 R 7 , q) —NR 7 C(S)OR 7 , r) —NR 7 C(S)NR 7 R 7 , s) —NR 7 C(NR 7 )NR 7 R 7 , t) —S(O) p R 7 , u) —SO 2 NR 7 R 7 , and v) R 7 ;
R 4 , at each occurrence, independently is selected from the group consisting of:
a) H, b) F, c) Cl, d) Br, e) I, f) ═O, g) ═S, h) ═NR 5 , i) ═NOR 5 , j) ═N—NR 5 R 5 , k) —CF 3 , l) —OR 5 , m) —CN, n) —NO 2 , o) —NR 5 R 5 , p) —C(O)R 5 , q) —C(O)OR 5 , r) —OC(O)R 5 , s) —C(O)NR 5 R 5 , t) —NR 5 C(O)R 5 , u) —OC(O)NR 5 R 5 , v) —NR 5 C(O)OR 5 , w) —NR 5 C(O)NR 5 R 5 , x) —C(S)R 5 , y) —C(S)OR 5 , z) —OC(S)R 5 , aa) —C(S)NR 5 R 5 , bb) —NR 5 C(S)R 5 , cc) —OC(S)NR 5 R 5 , dd) —NR 5 C(S)OR 5 , ee) —NR 5 C(S)NR 5 R 5 , ff) —NR 5 C(NR 5 )NR 5 R 5 , gg) —S(O) p R 5 , and hh) R 5 ;
R 5 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) —C(OC 1-6 alkyl, f) —C(O)C 2-6 alkenyl, g) —C(O)—C 2-6 alkynyl, h) —C(O)O—C 1-6 alkyl, i) —C(O)O—C 2-6 alkenyl, and j) —C(O)O—C 2-6 alkynyl,
wherein any of b)-j) optionally is substituted with one or more R 6 groups;
R 6 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, and u) —S(O) p C 1-6 alkyl;
R 7 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more R 8 groups;
R 8 , at each occurrence, is independently selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) ═0, f) ═S, g) ═NR 9 , h) ═NOR 9 , i) ═N—NR 9 R 9 , j) —CF 3 , k) —OR 9 , l) —CN, m) —NO 2 , n) —NR 9 R 9 , o) —C(O)R 9 , p) —C(O)OR 9 , q) —OC(O)R 9 , r) —C(O)NR 9 R 9 , s) —NR 9 C(O)R 9 , t) —OC(O)NR 9 R 9 , u) —NR 9 C(O)OR 9 , v) —NR 9 C(O)NR 9 R 9 , w) —C(S)R 9 , x) —C(S)OR 9 , y) —OC(S)R 9 , z) —C(S)NR 9 R 9 , aa) —NR 9 C(S)R 9 , bb) —OC(S)NR 9 R 9 , cc) —NR 9 C(S)OR 9 , dd) —NR 9 C(S)NR 9 R 9 , ee) —NR 9 C(NR 9 )NR 9 R 9 , ff) —S(O) p R 9 , gg) —SO 2 NR 9 R 9 , and hh) R 9 ;
R 9 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)—C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)— 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more moieties selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, u) —SO 2 NH 2 —, v) —SO 2 NHC 1-6 alkyl, w) —SO 2 N(C 1-6 alkyl) 2 , and x) —S(O) p C 1-6 alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, or 4; and
p, at each occurrence, independently is 0, 1, or 2.
68 . A method of treating a disorder in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds having the formula:
or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein:
A is phenyl;
B is selected from the group consisting of:
phenyl, pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl;
Het-CH 2 —R 3 is selected from the group consisting of:
M is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein
i) any of a)-c) is substituted with one or more moieties selected from the group consisting of F, Cl, Br, and I; and
ii) any of a)-c) optionally is further substituted with one or more R 4 groups;
X is selected from the group consisting of:
a) —, b) —NR 5 —, c) —N(O)—, d) —N(OR 5 )—, e) —S(O) p —, f) —NR 5 —N═, g) ═N—NR 5 —, h) —O—N═, i) ═N—O—, j) —N═, k) ═N—, l) —NR 5 —NR 5 —, m) —NR 5 C(O)O—, n) —OC(O)NR 5 —, o) —NR 5 C(O)NR 5 —, p) —NR 5 C(NR 5 )NR 5 —, and
L is selected from the group consisting of:
a) C 1-6 alkyl, b) C 2-6 alkenyl, and c) C 2-6 alkynyl,
wherein any of a)-c) optionally is substituted with one or more R 4 groups;
R 1 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 2 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OR 7 , g) —CN, h) —NO 2 , i) —NR 7 R 7 , j) —C(O)R 7 , k) —C(O)OR 7 , l) —OC(O)R 7 , m) —C(O)NR 7 R 7 , n) —NR 7 C(O)R 7 , o) —OC(O)NR 7 R 7 , p) —NR 7 C(O)OR 7 , q) —NR 7 C(O)NR 7 R 7 , r) —C(S)R 7 , s) —C(S)OR 7 , t) —OC(S)R 7 , u) —C(S)NR 7 R 7 , v) —NR 7 C(S)R 7 , w) —OC(S)NR 7 R 7 , x) —NR 7 C(S)OR 7 , y) —NR 7 C(S)NR 7 R 7 , z) —NR 7 C(NR 7 )NR 7 R 7 , aa) —S(O) p R 7 , bb) —SO 2 NR 7 R 7 , and cc) R 7 ;
R 3 is selected from the group consisting of:
a) —OR 7 , b) —NR 7 R 7 , c) —C(O)R 7 , d) —C(O)OR 7 , e) —OC(O)R 7 , f) —C(O)NR 7 R 7 , g) —NR 7 C(O)R 7 , h) —OC(O)NR 7 R 7 , i) —NR 7 C(O)OR 7 , j) —NR 7 C(O)NR 7 R 7 , k) —C(S)R 7 , l) —C(S)OR 7 , m) —OC(S)R 7 , n) —C(S)NR 7 R 7 , o) —NR 7 C(S)R 7 , p) —OC(S)NR 7 R 7 , q) —NR 7 C(S)OR 7 , r) —NR 7 C(S)NR 7 R 7 , s) —NR 7 C(NR 7 )NR 7 R 7 , t) —S(O) p R 7 , u) —SO 2 NR 7 R 7 , and v) R 7 ;
R 4 , at each occurrence, independently is selected from the group consisting of:
a) H, b) F, c) Cl, d) Br, e) I, f) ═O, g) ═S, h) ═NR 5 , i) ═NOR 5 , j) ═N—NR 5 R 5 , k) —CF 3 , l) —OR 5 , m) —CN, n) —NO 2 , o) —NR 5 R 5 , p) —C(O)R 5 , q) —C(O)OR 5 , r) —OC(O)R 5 , s) —C(O)NR 5 R 5 , t) —NR 5 C(O)R 5 , u) —OC(O)NR 5 R 5 , v) —NR 5 C(O)OR 5 , w) NR 5 C(O)NR 5 R 5 , x) —C(S)R 5 , y) —C(S)OR 5 , z) —OC(S)R 5 , aa) —C(S)NR 5 R 5 , bb) —NR 5 C(S)R 5 , cc) —OC(S)NR 5 R 5 , dd) —NR 5 C(S)OR 5 , ee) —NR 5 C(S)NR 5 R 5 , ff) —NR 5 C(NR 5 )NR 5 R 5 , gg) —S(O) p R 5 , and hh) R 5 ;
R 5 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) —C(O)C 1-6 alkyl, f) —C(O)—C 2-6 alkenyl, g) —C(O)—C 2-6 alkynyl, h) —C(O)O—C 1-6 alkyl, i) —C(O)O—C 2-6 alkenyl, and j) —C(O)O—C 2-6 alkynyl,
wherein any of b)-j) optionally is substituted with one or more R 6 groups;
R 6 , at each occurrence, independently is selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, and u) —S(O) p C 1-6 alkyl;
R 7 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more R 8 groups;
R 8 , at each occurrence, is independently selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) ═O, f) ═S, g) ═NR 9 , h) ═NOR 9 , i) ═N—NR 9 R 9 , j) —CF 3 , k) —OR 9 , l) —CN, m) —NO 2 , n) —NR 9 R 9 , o) —C(O)R 9 , p) —C(O)OR 9 , q) —OC(O)R 9 , r) —C(O)NR 9 R 9 , s) —NR 9 C(O)R 9 , t) —OC(O)NR 9 R 9 , u) —NR 9 C(O)OR 9 , v) —NR 9 C(O)NR 9 R 9 , w) —C(S)R 9 , x) —C(S)OR 9 , y) —OC(S)R 9 , z) —C(S)NR 9 R 9 , aa) —NR 9 C(S)R 9 , bb) —OC(S)NR 9 R 9 , cc) —NR 9 C(S)OR 9 , dd) —NR 9 C(S)NR 9 R 9 , ee) —NR 9 C(NR 9 )NR 9 R 9 , ff) —S(O) p R 9 , gg) —SO 2 NR 9 R 9 , and hh) R 9 ;
R 9 , at each occurrence, independently is selected from the group consisting of:
a) H, b) C 1-6 alkyl, c) C 2-6 alkenyl, d) C 2-6 alkynyl, e) C 3-14 saturated, unsaturated, or aromatic carbocycle, f) 3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, g) —C(O)—C 1-6 alkyl, h) —C(O)C 2-6 alkenyl, i) —C(O)C 2-6 alkynyl, j) —C(O)—C 3-14 saturated, unsaturated, or aromatic carbocycle, k) —C(O)-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, l) —C(O)O—C 1-6 alkyl, m) —C(O)O—C 2-6 alkenyl, n) —C(O)O—C 2-6 alkynyl, o) —C(O)O—C 3-14 saturated, unsaturated, or aromatic carbocycle, and p) —C(O)O-3-14 membered saturated, unsaturated, or aromatic heterocycle consisting of one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,
wherein any of b)-p) optionally is substituted with one or more moieties selected from the group consisting of:
a) F, b) Cl, c) Br, d) I, e) —CF 3 , f) —OH, g) —OC 1-6 alkyl, h) —SH, i) —SC 1-6 alkyl, j) —CN, k) —NO 2 , l) —NH 2 , m) —NHC 1-6 alkyl, n) —N(C 1-6 alkyl) 2 , o) —C(O)C 1-6 alkyl, p) —C(O)OC 1-6 alkyl, q) —C(O)NH 2 , r) —C(O)NHC 1-6 alkyl, s) —C(O)N(C 1-6 alkyl) 2 , t) —NHC(O)C 1-6 alkyl, u) —SO 2 NH 2 —, v) —SO 2 NHC 1-6 alkyl, w) —SO 2 N(C 1-6 alkyl) 2 , and x) —S(O) p C 1-6 alkyl;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, 3, or 4; and
p, at each occurrence, independently is 0, 1, or 2;
thereby to ameliorate a symptom of the disorder, wherein the disorder is selected from the group consisting of: a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant Staphylococcus aureus infection, a vancomycin-resistant Enterococci infection, a linezolid-resistant organism infection, and tuberculosis.
69 . The method according to claim 67 , wherein the compound is administered orally, parentally, or topically.
70 . The method according to claim 68 , wherein the compound is administered orally, parentally, or topically.
71 . A method of treating a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds having the structure corresponding to any one of the compounds listed below:
Compound
Number
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
or a pharmaceutically acceptable salt, ester or prodrug thereof.
72 . A method of treating a disorder in a mammal comprising the step of administering to the mammal an effective amount of one or more compounds having the structure corresponding to any one of the compounds listed below:
Compound
Number
Structure
1
2
3
4
5
6
7
8
9
10
11
12
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
or a pharmaceutically acceptable salt, ester or prodrug thereof,
thereby to ameliorate a symptom of the disorder, wherein the disorder is selected from the group consisting of: a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant Staphylococcus aureus infection, a vancomycin-resistant Enterococci infection, a linezolid-resistant organism infection, and tuberculosis.
73 . The method according to claim 71 , wherein the compound is administered orally, parentally, or topically.
74 . The method according to claim 72 , wherein the compound is administered orally, parentally, or topically.
75 . A method of treating a microbial infection in a mammal comprising the step of administering to the mammal an effective amount of a compound having the structure
or a pharmaceutically acceptable salt or prodrug thereof.
76 . A method according to claim 75 comprising administering a pharmaceutically acceptable salt of the compound.
77 . A method according to claim 76 wherein said salt is a monohydrochloride salt.
78 . A method of treating a disorder in a mammal comprising the step of administering to the mammal an effective amount of a compound having the structure
or a pharmaceutically acceptable salt or prodrug thereof;
thereby to ameliorate a symptom of the disorder, wherein the disorder is selected from the group consisting of: a skin infection, nosocomial pneumonia, post-viral pneumonia, an abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio-ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin-resistant Staphylococcus aureus infection, a vancomycin-resistant Enterococci infection, a linezolid-resistant organism infection, and tuberculosis.
79 . A method according to claim 78 comprising administering a pharmaceutically acceptable salt of the compound.
80 . A method according to claim 79 wherein said salt is a monohydrochloride salt.
81 . The method according to claim 75 , wherein the compound is administered orally, parentally, or topically.
82 . The method according to claim 76 , wherein the compound is administered orally, parentally, or topically.
83 . The method according to claim 77 , wherein the compound is administered orally, parentally, or topically.
84 . The method according to claim 78 , wherein the compound is administered orally, parentally, or topically.
85 . The method according to claim 79 , wherein the compound is administered orally, parentally, or topically.
86 . The method according to claim 80 , wherein the compound is administered orally, parentally, or topically.Join the waitlist — get patent alerts
Track US2006148869A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.